Covalon’s SurgiClear Dressing Plays an Important Role in Preventing Surgical Wound Infections at Top Children’s Hospital

Two-year study to prevent sternal wound infections highlights SurgiClear as key part of infection prevention package used to significantly reduce infection rates

MISSISSAUGA, ON, November 21, 2022 /PRNewswire/ – Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV) (OTCQX: CVALF), an advanced medical technology company, today announced that its SurgiClear® The dressing played a key role in an infection prevention package that significantly reduced surgical wound infections in a recently published two-year quality improvement study from Intermountain Primary Children’s Hospital, a children’s hospital in non-profit associated with University of Utah and part of the Intermountain Healthcare system.1 Intermountain Primary Children’s Hospital is recognized as one of the best children’s hospitals in United States.

SurgiClear® protecting a cardiac surgical incision in a newborn. (CNW Group/Covalon Technologies Ltd.)

Describing the impact of the bundled intervention, published in The Annals of Thoracic Surgeryauthors from Intermountain Healthcare report that the annual rate of total surgical wound infections decreased from 2.83% in 2019 to 1.15% in 2021. The cluster approach used to improve perioperative infection prevention practices included the implementation of SurgiClear as the main change in practice.

Jeremy HarmanPA-C, an author of the study, commented: “The trifecta of breathable barrier protection, antimicrobials and the ability to monitor the site is what makes it a great dressing. It’s easier for us to assess the wound and it is more comfortable for the patients.”

The goal of the project was to reduce the rate of surgical wound infections to less than 1.5% in pediatric cardiothoracic surgery patients. Surgical wound infections are a common complication of cardiac surgery, associated with prolonged hospital stay, readmissions, higher cost of care, and increased mortality. Pediatric cardiology centers across the United States that focus on process improvement are investing in preventative strategies and quality improvement protocols to reduce the risk of surgical site infections. State-of-the-art technology, such as Covalon’s SurgiClear, can help standardize postoperative wound care.

“It’s great to see another institution share their experience with our SurgiClear dressing through a post,” said Brian Peddler, CEO. “At Covalon, we are committed to providing better patient and clinician experiences, and this work from Intermountain Primary Children’s Hospital shows how best practices and products come together to do just that, helping the most vulnerable recover. .”

SurgiClear is a dual antimicrobial, transparent silicone surgical dressing that provides full site visibility, allowing inspection of surgical wound sites, while minimizing contact and repetitive dressing removal. Its dual antimicrobial silicone technology provides broad-spectrum protection against gram-positive and gram-negative bacteria that’s gentle on even the most sensitive skin.

In addition to SurigClear, other infection prevention solutions from Covalon include:

  • VALGuard® – A clear, FDA-listed environmental barrier designed to protect catheter hubs and line connections from external contaminants and gross contamination, including bodily fluids and other secretions. It incorporates a quick release pull band for quick access to infusion hubs and for easy removal.

  • IV Delete® – an antimicrobial vascular access dressing that provides complete transparency at and around the insertion site for easy daily assessment. It uses a soft silicone adhesive to preserve the skin’s barrier function and minimize skin damage and incorporates safe amounts of antimicrobials, without sacrificing efficacy, to protect against chemical irritation.

Healthcare providers interested in learning more about Covalon’s solutions can visit or follow Covalon on LinkedIn, Facebook, instagram Where Twitter.


  1. Glenn, ET, Harman, JR, Marietta, J., Lake, J., Bailly, DK, Ou, Z., Griffiths, ER, & Ware, AL (2022). Impact of a surgical wound infection prevention package in pediatric cardiothoracic surgery. The Annals of Thoracic Surgery.

About Covalon
Covalon Technologies Ltd. is a researcher, developer, manufacturer and marketer of patent-protected medical products that improve patient outcomes and save lives in the areas of advanced wound care, infection management and surgical procedures. Covalon leverages its patented medical technology platforms and expertise in two ways: (i) by developing products sold under the Covalon name; and (ii) developing and commercializing medical products for other medical companies under development and license agreements. The Company is listed on the TSX Venture Exchange under the symbol COV and trades on the OTQX market under the symbol CVALF. To learn more about Covalon, visit our website at

Twitter: @covalon

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This press release may contain forward-looking statements that reflect the Company’s current expectations regarding future events. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “plan”, “estimate”, “expect”, “intend” or variations of these words and expressions or indicate that certain actions, events or results “could”, “could”, “would”, “could”, “will” or “will be undertaken”, “will occur” or “will be achieved”. expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but rather represent management’s expectations, estimates and projections regarding future events. Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in more detail in the “Risks and Uncertainties” section of our MD&A and Discussion of Financial Condition and Results of operating for the three and nine months ended June 30, 2022available on the company profile at, each of which could cause results, performance or achievements to differ materially from the results discussed or implied by the forward-looking statements. Investors should not place undue reliance on forward-looking statements. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company assumes no obligation to update or change any forward-looking statements, whether as a result of new information, other events or otherwise, except as required by law.

Covalon Technologies Ltd. Logo (CNW Group/Covalon Technologies Ltd.)

Covalon Technologies Ltd. Logo (CNW Group/Covalon Technologies Ltd.)



Show original content to download multimedia:

SOURCECovalon Technologies Ltd.

Christine E. Phillips